Meeting Abstract
BibTex RIS Cite

THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Year 2022, Volume: 5 Issue: S-1, 31 - 31, 09.08.2022
https://doi.org/10.26650/JARHS2021-1138755

Abstract

Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.

References

  • Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5-12

THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Year 2022, Volume: 5 Issue: S-1, 31 - 31, 09.08.2022
https://doi.org/10.26650/JARHS2021-1138755

Abstract

Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.

References

  • Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5-12
There are 1 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Meeting Abstract
Authors

Esra Esmeray Sönmez This is me 0000-0003-3159-2005

Tevfik Hatipoğlu This is me 0000-0001-9331-6749

Xiaozhou Hu This is me 0000-0002-7872-8910

Hongling Yuan This is me 0000-0002-4858-2471

Ayça Erşen Danyeli This is me 0000-0001-8015-9916

Ayla Anar Arıcı This is me 0000-0003-2563-5654

Ahmet Şeyhanlı 0000-0001-6082-2995

Zühal Önder Siviş 0000-0002-3499-1864

Bengü Demirağ This is me 0000-0001-5213-7162

Eda Ataseven 0000-0003-3419-5814

Dilek İnce 0000-0002-7914-7886

Zekiye Altun 0000-0002-1558-4534

Safiye Aktaş 0000-0002-7658-5565

İnci Alacacıoğlu 0000-0002-8187-7159

Tuğba Süzek 0000-0002-3243-1759

Nazan Özsan This is me 0000-0001-7844-972X

Taner Kemal Erdağ 0000-0001-5636-3343

Elvan Caglar Citak 0000-0003-1451-1373

Sermin Özkal 0000-0002-8167-0238

Mehmet Ali Özcan 0000-0001-7842-9702

Nazan Çetingül 0000-0002-1768-028X

Erdener Özer 0000-0001-5743-5222

Tezer Kutluk 0000-0002-1918-4407

Nur Olgun 0000-0001-9591-0207

Can Küçük This is me 0000-0001-5540-9012

Publication Date August 9, 2022
Submission Date July 10, 2022
Published in Issue Year 2022 Volume: 5 Issue: S-1

Cite

MLA Sönmez, Esra Esmeray et al. “THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND MiRNA-SEQ OF B CELL LYMPHOMAS”. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, vol. 5, no. S-1, 2022, pp. 31-31, doi:10.26650/JARHS2021-1138755.